Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53


Long-term persistence of zoster vaccine efficacy.

Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman CA, Marques A, Toney J, Boardman K, Su SC, Li X, Chan IS, Parrino J, Annunziato P, Oxman MN; Shingles Prevention Study Group.

Clin Infect Dis. 2015 Mar 15;60(6):900-9. doi: 10.1093/cid/ciu918. Epub 2014 Nov 20.


Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo.

Abdel-Mohsen M, Deng X, Liegler T, Guatelli JC, Salama MS, Ghanem Hel-D, Rauch A, Ledergerber B, Deeks SG, Günthard HF, Wong JK, Pillai SK.

J Virol. 2014 Jan;88(1):763-7. doi: 10.1128/JVI.02687-13. Epub 2013 Oct 23.


Safety of zoster vaccine in elderly adults following documented herpes zoster.

Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR, Toney JF, Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA, Yeh SS, Davis LE, Crawford GE, Neuzil KM, Johnson GR, Zhang JH, Harbecke R, Chan IS, Keller PM, Williams HM, Boardman KD, Silber JL, Annunziato PW; Shingles Prevention Study Group.

J Infect Dis. 2013 Aug 15;208(4):559-63. doi: 10.1093/infdis/jit182. Epub 2013 Apr 30.


Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.

Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P; Shingles Prevention Study Group.

Clin Infect Dis. 2012 Nov 15;55(10):1320-8. doi: 10.1093/cid/cis638. Epub 2012 Jul 24.


Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu.

Tokarev AA, Munguia J, Guatelli JC.

J Virol. 2011 Jan;85(1):51-63. doi: 10.1128/JVI.01795-10. Epub 2010 Oct 27.


BST-2 mediated restriction of simian-human immunodeficiency virus.

Ruiz A, Lau D, Mitchell RS, Hill MS, Schmitt K, Guatelli JC, Stephens EB.

Virology. 2010 Oct 25;406(2):312-21. doi: 10.1016/j.virol.2010.07.021. Epub 2010 Aug 13.


BST-2/tetherin: a new component of the innate immune response to enveloped viruses.

Evans DT, Serra-Moreno R, Singh RK, Guatelli JC.

Trends Microbiol. 2010 Sep;18(9):388-96. doi: 10.1016/j.tim.2010.06.010. Epub 2010 Aug 3. Review.


HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.

Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM.

Retrovirology. 2010 Jun 7;7:51. doi: 10.1186/1742-4690-7-51. Erratum in: Retrovirology. 2011;8:85.


The Vpu protein: new concepts in virus release and CD4 down-modulation.

Ruiz A, Guatelli JC, Stephens EB.

Curr HIV Res. 2010 Apr;8(3):240-52. Review.


An MHC-I cytoplasmic domain/HIV-1 Nef fusion protein binds directly to the mu subunit of the AP-1 endosomal coat complex.

Singh RK, Lau D, Noviello CM, Ghosh P, Guatelli JC.

PLoS One. 2009 Dec 18;4(12):e8364. doi: 10.1371/journal.pone.0008364.


Interactions of viral protein U (Vpu) with cellular factors.

Guatelli JC.

Curr Top Microbiol Immunol. 2009;339:27-45. doi: 10.1007/978-3-642-02175-6_2. Review.


Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.

Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC.

PLoS Pathog. 2009 May;5(5):e1000450. doi: 10.1371/journal.ppat.1000450. Epub 2009 May 29.


Competition model for upregulation of the major histocompatibility complex class II-associated invariant chain by human immunodeficiency virus type 1 Nef.

Mitchell RS, Chaudhuri R, Lindwasser OW, Tanaka KA, Lau D, Murillo R, Bonifacino JS, Guatelli JC.

J Virol. 2008 Aug;82(16):7758-67. doi: 10.1128/JVI.02668-07. Epub 2008 Jun 4.


Maintenance of Nef-mediated modulation of major histocompatibility complex class I and CD4 after sexual transmission of human immunodeficiency virus type 1.

Noviello CM, Pond SL, Lewis MJ, Richman DD, Pillai SK, Yang OO, Little SJ, Smith DM, Guatelli JC.

J Virol. 2007 May;81(9):4776-86. Epub 2007 Feb 28.


A computer-based, image-analysis method to quantify HIV-1 infection in a single-cycle infectious center assay.

Day JR, Martínez LE, Sásik R, Hitchin DL, Dueck ME, Richman DD, Guatelli JC.

J Virol Methods. 2006 Oct;137(1):125-33. Epub 2006 Jul 28.


Modulation of cellular protein trafficking by human immunodeficiency virus type 1 Nef: role of the acidic residue in the ExxxLL motif.

Coleman SH, Madrid R, Van Damme N, Mitchell RS, Bouchet J, Servant C, Pillai S, Benichou S, Guatelli JC.

J Virol. 2006 Feb;80(4):1837-49.


HIV-1 Nef stabilizes AP-1 on membranes without inducing ARF1-independent de novo attachment.

Coleman SH, Hitchin D, Noviello CM, Guatelli JC.

Virology. 2006 Feb 5;345(1):148-55. Epub 2005 Oct 25.


The HIV-1 Nef protein as a target for antiretroviral therapy.

Coleman SH, Day JR, Guatelli JC.

Expert Opin Ther Targets. 2001 Feb;5(1):1-22.


A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL; Shingles Prevention Study Group.

N Engl J Med. 2005 Jun 2;352(22):2271-84.


Leucine-specific, functional interactions between human immunodeficiency virus type 1 Nef and adaptor protein complexes.

Coleman SH, Van Damme N, Day JR, Noviello CM, Hitchin D, Madrid R, Benichou S, Guatelli JC.

J Virol. 2005 Feb;79(4):2066-78.


Broadly increased sensitivity to cytotoxic T lymphocytes resulting from Nef epitope escape mutations.

Ali A, Pillai S, Ng H, Lubong R, Richman DD, Jamieson BD, Ding Y, McElrath MJ, Guatelli JC, Yang OO.

J Immunol. 2003 Oct 15;171(8):3999-4005.


Two independent regions of HIV-1 Nef are required for connection with the endocytic pathway through binding to the mu 1 chain of AP1 complex.

Erdtmann L, Janvier K, Raposo G, Craig HM, Benaroch P, Berlioz-Torrent C, Guatelli JC, Benarous R, Benichou S.

Traffic. 2000 Nov;1(11):871-83.


The dileucine-based sorting motif in HIV-1 Nef is not required for down-regulation of class I MHC.

Riggs NL, Craig HM, Pandori MW, Guatelli JC.

Virology. 1999 Jun 5;258(2):203-7.


Cell-associated viral RNA expression during acute infection with HIV type 1.

Riggs NL, Little SJ, Richman DD, Guatelli JC.

AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1141-9.


Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy.

Günthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, Richman DD.

J Virol. 1998 Mar;72(3):2422-8.


The positive influence of Nef on viral infectivity.

Guatelli JC.

Res Virol. 1997 Jan-Feb;148(1):34-7. Review. No abstract available.


Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein.

Pandori MW, Fitch NJ, Craig HM, Richman DD, Spina CA, Guatelli JC.

J Virol. 1996 Jul;70(7):4283-90.


Production and characterization of high-titer stocks of rev-defective HIV-1.

Riggs NL, Guatelli JC.

Virology. 1996 Mar 15;217(2):602-6.


Cell surface CD4 downregulation and resistance to superinfection induced by a defective provirus of HIV-1.

Little SJ, Riggs NL, Chowers MY, Fitch NJ, Richman DD, Spina CA, Guatelli JC.

Virology. 1994 Dec;205(2):578-82.


Biological importance and cooperativity of HIV-1 regulatory gene splice acceptors.

Riggs NL, Little SJ, Richman DD, Guatelli JC.

Virology. 1994 Jul;202(1):264-71.


Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene.

Chowers MY, Spina CA, Kwoh TJ, Fitch NJ, Richman DD, Guatelli JC.

J Virol. 1994 May;68(5):2906-14.


Mechanisms for the inhibition of HIV replication by interferons-alpha, -beta, and -gamma in primary human macrophages.

Meylan PR, Guatelli JC, Munis JR, Richman DD, Kornbluth RS.

Virology. 1993 Mar;193(1):138-48.


Ordered appearance of human immunodeficiency virus type 1 nucleic acids following high multiplicity infection of macrophages.

Munis JR, Kornbluth RS, Guatelli JC, Richman DD.

J Gen Virol. 1992 Aug;73 ( Pt 8):1899-906.


Use of self-sustained sequence replication amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus.

Gingeras TR, Prodanovich P, Latimer T, Guatelli JC, Richman DD, Barringer KJ.

J Infect Dis. 1991 Dec;164(6):1066-74.


Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction.

Richman DD, Guatelli JC, Grimes J, Tsiatis A, Gingeras T.

J Infect Dis. 1991 Dec;164(6):1075-81.


Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication.

Guatelli JC, Whitfield KM, Kwoh DY, Barringer KJ, Richman DD, Gingeras TR.

Proc Natl Acad Sci U S A. 1990 Oct;87(19):7797. No abstract available.


Methodologies for in vitro nucleic acid amplification and their applications.

Gingeras TR, Richman DD, Kwoh DY, Guatelli JC.

Vet Microbiol. 1990 Sep;24(3-4):235-51. Review.


Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication.

Guatelli JC, Whitfield KM, Kwoh DY, Barringer KJ, Richman DD, Gingeras TR.

Proc Natl Acad Sci U S A. 1990 Mar;87(5):1874-8. Erratum in: Proc Natl Acad Sci U S A 1990 Oct;87(19):7797.

Supplemental Content

Loading ...
Support Center